Nurix Therapeutics, Inc. (NRIX) — SEC Financial Statements & Analysis

Nurix Therapeutics, Inc. (NRIX) is a pharmaceutical preparations company, incorporated in DE. Nurix Therapeutics, Inc. trades on Nasdaq as: NRIX. Nurix Therapeutics, Inc. (NRIX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-05-31, filed with the SEC on 2026-07-09. Based on that filing, Nurix Therapeutics, Inc. carries a market cap of $1.97B, a P/E ratio of -5.78x, a P/B ratio of 4.90x, a P/S ratio of 53.66x, an enterprise value of $1.90B, and an EV/EBITDA multiple of -5.40x. On profitability, it posts an operating margin of -982.37%, a net margin of -928.44%, a Return on Equity (ROE) of -80.30%, a Return on Assets (ROA) of -60.57%, and a Return on Invested Capital (ROIC) of -103.14%. Per share, it reports EPS of $-3.07, diluted EPS of $-3.07, free cash flow per share of $-2.74, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -58.40% year-over-year, net income growth of 64.65% year-over-year, and EPS growth of 24.33% year-over-year. On the balance sheet, it maintains a current ratio of 6.34x, a quick ratio of 6.16x, working capital of $384.46M, a debt-to-equity ratio of 0.33x, a debt ratio of 0.25, free cash flow of $-304.53M (TTM), and net debt of $-68.65M. Figures sourced from SEC EDGAR.

Market Cap

$1.97B

P/E TTM

-5.78x

EPS TTM

$-3.07

P/B TTM

4.90x

ROE TTM

-80.30%

ROA TTM

-60.57%

Debt To Equity

0.33x

Free Cash Flow TTM

$-304.53M

Net Revenue TTM Growth 1Y

-58.40%

Data as of 2026-05-31 · Source: SEC EDGAR